<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220311</url>
  </required_header>
  <id_info>
    <org_study_id>303530</org_study_id>
    <secondary_id>90699</secondary_id>
    <nct_id>NCT00220311</nct_id>
  </id_info>
  <brief_title>A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia</brief_title>
  <official_title>A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the efficacy and safety of fludarabine phosphate&#xD;
      administered with dose increasing in 6 cycles (1 cycle: 5 treatment days every 28 days) in&#xD;
      untreated chronic lymphocytic leukemia (CLL) patients with anemia and/or thrombocytopenia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As of 29 May 2009, the clinical trial sponsor is Genzyme Corporation. NOTE: This study was&#xD;
      originally posted by sponsor Schering AG, Germany, which was subsequently renamed to Bayer&#xD;
      Schering Pharma AG, Germany.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2000</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate of final overall evaluation up to 6 treatment cycles (at about 6 months)</measure>
    <time_frame>Up to 6 treatment cycles (at about 6 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate for measurable lesions / evaluable lesions / peripheral blood findings / bone marrow findings</measure>
    <time_frame>Up to 6 treatment cycles (at about 6 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response and change of peripheral blood findings</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate (Fludara)</intervention_name>
    <description>6 cycles (1 cycle: 5 treatment days every 28 days)</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>BAY86-4864</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed CLL&#xD;
&#xD;
          -  Patients with hemoglobin concentration and/or platelet count below the institution's&#xD;
             lower limit of normal&#xD;
&#xD;
          -  Patients who have not received cancer chemotherapy or radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with apparent infections (including viral infections)&#xD;
&#xD;
          -  Patients with serious complications (heart, liver, or kidney disease, etc.)&#xD;
&#xD;
          -  Patients with a serious bleeding tendency (e.g., DIC)&#xD;
&#xD;
          -  Patients with serious CNS symptoms&#xD;
&#xD;
          -  Patients with fever &gt;= 38Â°C (excluding tumor fever)&#xD;
&#xD;
          -  Patients with interstitial pneumonia or pulmonary fibrosis&#xD;
&#xD;
          -  Patients with active multiple cancers&#xD;
&#xD;
          -  Patients receiving other investigational products within 6 months before registration&#xD;
             in this study&#xD;
&#xD;
          -  Patients with prior allergies to medications that are similar to the investigational&#xD;
             product (purine nucleoside derivatives)&#xD;
&#xD;
          -  Women who are pregnant, of childbearing potential, or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Genzyme, a Sanofi Company</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

